Literature DB >> 29872891

[Inflammatory bowel diseases : Crohn's disease and ulcerative colitis].

S Fischer1, T Rath2, M F Neurath2.   

Abstract

Inflammatory bowel diseases (IBD) are complex diseases. Epidemiological studies suggest rising incidences in industrialized countries. The article is based on a literature search in PubMed and is oriented on the current guidelines published by the European Crohn's and Colitis Organisation. IBD are characterized by chronic diarrhoea, abdominal pain and peranal haemorrhage. Extraintestinal manifestations commonly affect joints, skin, eyes and bile tracts. Early diagnosis and therapeutic intervention determine individual patient outcome. Medical treatment currently includes aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors and biologicals. IBDs require anti-inflammatory and if necessary immunosuppressive therapy. Due to extraintestinal complications and the possible need for surgical intervention, an interdisciplinary approach is important.

Entities:  

Keywords:  Algorithms, treatment; Biologics; Calprotectin; Glucocorticoids; Microbiome

Mesh:

Substances:

Year:  2018        PMID: 29872891     DOI: 10.1007/s00108-018-0442-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

Review 1.  Smoking and inflammatory bowel disease.

Authors:  D T Rubin; S B Hanauer
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-08       Impact factor: 2.566

Review 2.  The Intestinal Microbiota in Inflammatory Bowel Disease.

Authors:  Christoph Becker; Markus F Neurath; Stefan Wirtz
Journal:  ILAR J       Date:  2015

Review 3.  Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature.

Authors:  Natasha-A Koloski; Laurel Bret; Graham Radford-Smith
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

Review 4.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

5.  Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease.

Authors:  Sandra Wenger; Susanna Nikolaus; Stefanie Howaldt; Bernd Bokemeyer; Andreas Sturm; Jan C Preiss; Alain M Schoepfer; Andreas Stallmach; Carsten Schmidt
Journal:  J Crohns Colitis       Date:  2011-07-18       Impact factor: 9.071

Review 6.  The epidemiology of inflammatory bowel disease.

Authors:  Johan Burisch; Pia Munkholm
Journal:  Scand J Gastroenterol       Date:  2015-02-17       Impact factor: 2.423

7.  Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.

Authors:  Jimmy Z Liu; Suzanne van Sommeren; Hailiang Huang; Siew C Ng; Rudi Alberts; Atsushi Takahashi; Stephan Ripke; James C Lee; Luke Jostins; Tejas Shah; Shifteh Abedian; Jae Hee Cheon; Judy Cho; Naser E Dayani; Lude Franke; Yuta Fuyuno; Ailsa Hart; Ramesh C Juyal; Garima Juyal; Won Ho Kim; Andrew P Morris; Hossein Poustchi; William G Newman; Vandana Midha; Timothy R Orchard; Homayon Vahedi; Ajit Sood; Joseph Y Sung; Reza Malekzadeh; Harm-Jan Westra; Keiko Yamazaki; Suk-Kyun Yang; Jeffrey C Barrett; Behrooz Z Alizadeh; Miles Parkes; Thelma Bk; Mark J Daly; Michiaki Kubo; Carl A Anderson; Rinse K Weersma
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 41.307

8.  IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis.

Authors:  Sarah Fischer; Erzsébet Kövesdi; Lili Magyari; Veronika Csöngei; Kinga Hadzsiev; Béla Melegh; Péter Hegyi; Patrícia Sarlós
Journal:  World J Gastroenterol       Date:  2017-01-21       Impact factor: 5.742

9.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

Authors:  Marcus Harbord; Rami Eliakim; Dominik Bettenworth; Konstantinos Karmiris; Konstantinos Katsanos; Uri Kopylov; Torsten Kucharzik; Tamás Molnár; Tim Raine; Shaji Sebastian; Helena Tavares de Sousa; Axel Dignass; Franck Carbonnel
Journal:  J Crohns Colitis       Date:  2017-07-01       Impact factor: 10.020

10.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

Authors:  Fernando Magro; Paolo Gionchetti; Rami Eliakim; Sandro Ardizzone; Alessandro Armuzzi; Manuel Barreiro-de Acosta; Johan Burisch; Krisztina B Gecse; Ailsa L Hart; Pieter Hindryckx; Cord Langner; Jimmy K Limdi; Gianluca Pellino; Edyta Zagórowicz; Tim Raine; Marcus Harbord; Florian Rieder
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 10.020

View more
  1 in total

Review 1.  Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Stefan Dübel; Reinhard E Voll
Journal:  Cells       Date:  2020-07-06       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.